COPENHAGEN--(BUSINESS WIRE)--Mirrx Therapeutics today announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking “Blockmir” technology, as well as to strengthen its intellectual property portfolio. Blockmirs are antisense oligonucleotides that bind to a microRNA binding site on an mRNA, blocking specific unwanted microRNA:mRNA interactions without interfering with normal cellular function. SEED Capital, Inventure Capital and Vecata Invest participated in the financing round.
